Phase IV, Non-comparative, Open Label, Multicenter, 28-Week Switching Study of Prasugrel Maintenance Dose From Clopidogrel in Patients With Acute Coronary Syndrome (ACS) Who Underwent a Percutaneous Coronary Intervention (PCI) in Taiwan
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs Prasugrel (Primary)
- Indications Acute coronary syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 02 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 12 Mar 2019 Planned End Date changed from 30 Jul 2020 to 30 Nov 2020.
- 12 Mar 2019 Planned primary completion date changed from 30 Jun 2020 to 31 Oct 2020.